-
Oppenheimer Bullish On Eiger Biopharmaceuticals Shares, Sees 71% Upside
Tuesday, July 5, 2016 - 1:41pm | 417Oppenheimer said Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) has lots of legs to run on given multiple data catalysts over the next 12–18 months and early human POC data in hepatitis D and hypoglycemia. Drug Pipeline Eiger's lead asset, Sarasar, is a farnesyltransferase inhibitor in...